Madrigal Pharmaceuticals, Inc. (MDGL)
UndervaluedFundamental
28
Price
$503.96
Market Cap
$11.64B
Part 1 · What the company is worth
Overview
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$1.28B
Trailing 12 months (through 6/30/2026)
Net Income
$-325M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$-190M
Total Equity
$603M
Total Liabilities
$657M
Current Ratio
3.20
Interest Coverage
10.24
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$682.11
Current Price
$503.96
Margin of Safety
+26.1%
Fair Value Range
$648.01 - $716.22
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-47.8%
P/B Ratio
22.23
P/FCF
-
Gross Margin
-
ROIC
-29.3%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-29.3%
WACC
7.9%
ROIC − WACC
-37.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (7)
- Price CAGR 42.47%
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Analyst Consensus 92% Buy
- Net Margin Trend -25.3% vs -54.7%
Failed (11)
- EPS shows upward trend
- ROIC -29.3%
- P/B Ratio 22.23
- Operating Margin -25.1%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -56.6%
- Earnings Surprise avg -90.7%
- Share Dilution 5.5%
- Piotroski F-Score 3/9
Unavailable (9)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. William J. Sibold | CEO, President & Director | 59 |
| Dr. Rebecca A. Taub M.D. | Founder, Senior Scientific & Medical Advisor and Director | 73 |
| Ms. Mardi C. Dier | Executive VP & CFO | 61 |
| Ms. Shannon Kelley | Executive VP, Chief Legal Officer & Corporate Secretary | 50 |
| Ms. Carole Huntsman | Executive VP & Chief Commercial Officer | 60 |
| Dr. David Soergel M.D. | Executive VP & Chief Medical Officer | 57 |
| Mr. Mark Underwood | Executive Vice President of Business Planning & Operations | - |
| Ms. Rita Thakkar | Senior VP & Chief Accounting Officer | 51 |
| Mr. Ronald Filippo | Executive VP & Chief Information Officer | - |
| Ms. Tina E. Ventura | Chief Investor Relations Officer | - |
Audit Risk
2
Board Risk
3
Compensation Risk
5
Shareholder Rights Risk
8
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-19
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-07-30
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-08-12
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for MDGL, sourced from Markets Gazette.
- 5/6/2026NEUTRALFull Transcript: Madrigal Pharmaceuticals Q1 2026 Earnings Call
Madrigal Pharmaceuticals Inc. held its Q1 2026 earnings call on May 6, 2026. While the transcript is available, the provided snippet does not contain specific financial results, forward-looking statements, or significant operational updates that would directly impact the company's stock valuation. Investors seeking to assess the company's performance and outlook should refer to the full earnings report and call transcript for detailed financial figures, management commentary on key business drivers, and any guidance provided for future periods. Without this detailed information, a definitive market impact cannot be determined.
- 3/17/2026POSITIVEThis Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally
Madrigal Pharmaceuticals, a clinical-stage biotech focused on NASH, obesity, and metabolic diseases, has seen its stock surge by an astonishing 1,300%. This remarkable rally has been further bolstered by a significant $181 million investment, underscoring strong investor confidence in the company's therapeutic pipeline. The substantial capital infusion is expected to accelerate clinical development and research efforts, potentially bringing its innovative small-molecule therapies closer to market approval. For investors, this dual validation of strong market performance and external financial backing signals robust growth prospects.
- 2/23/2026NEUTRALMadrigal (MDGL) Q4 2025 Earnings Call Transcript
Madrigal Pharmaceuticals has released the transcript of its fourth-quarter 2025 earnings conference call. While the news itself is informational, the document is a crucial resource for investors. Analysts and shareholders can now scrutinize the management's detailed commentary on financial performance, drug pipeline progress, and the strategic outlook for the future. The question-and-answer session will be of particular interest, as it often reveals nuances and details not found in official press releases. The availability of this comprehensive documentation allows for a deeper analysis, but does not in itself provide a directional signal until its contents are fully digested by the market.
via Markets Gazette